Condition: CRC (Colorectal Cancer) · Melanoma (Skin Cancer) · HCC - Hepatocellular Carcinoma · Sponsor: Hefei TG ImmunoPharma Co., Ltd.
This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in combination with Nivolumab in subjects with unresectable locally advanced/metastatic solid tumors. The study consists of two parts: TGI-5 monotherapy (Phase 1a: including a dose escalation part and a dose expansion part), TGI-5 in combination with a fixed dose of Nivolumab (Phase 1b: including a dose escalation part and a dose expansion part).
This description comes directly from the study's public registry record.
Hang Zhou, Bachelor · +86-0551-62861151 · hang.zhou@tgimmunopharma.com
Xiaohu Zheng, Doctorate · +86-0551-62861151 · xiaohu.zheng@tgimmunopharma.com
Always discuss trial participation with your own doctor first.
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07376707